Long-acting injectable form of HIV prevention outperforms daily pill in NIH study
Wednesday, July 8, 2020 - 09:30
in Health & Medicine
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National […]